TRT Kingdom review

TRT Kingdom's navigation promises four categories and one of them is empty: its Peptides category, from every page of the site, reads "No items found." for both the men's and women's columns, and the site has no peptide product page at all. What genuinely exists sits under Wellness — sermorelin with its own page at $233 a month on a three-month plan, plus bremelanotide (PT-141), NAD⁺ at $79 a month on a 2.5-month plan, glutathione and B12. Its hormone line is the real business: testosterone cypionate, enclomiphene, HCG, FSH and nandrolone. Everything is plan-shaped, nothing is month-to-month, and labs are billed separately at $149 every six months.

TRT Kingdom is a hormone-therapy telehealth platform co-founded by bodybuilder Jay Cutler, with Daniel Olivero as chief medical officer and nurse practitioners including Joseph Lacourse and Amber Thomas on staff. Its catalog runs four categories: Hormone Therapy (testosterone cypionate therapy, enclomiphene, HCG, follicle-stimulating hormone, nandrolone decanoate and an oral testosterone derivative for men; testosterone injections alone or with progesterone and estrogen for women), Peptides (empty), Weight Loss (compounded GLP-1 and GLP-1/GIP plus microdosing variants, phentermine, Lipo B, L-carnitine) and Wellness (sermorelin, PT-141, NAD⁺, glutathione, B12, modafinil, sildenafil, tadalafil).

Asynchronous by default, with lab work required before hormone therapy and a synchronous consultation available if a provider decides one is needed. Its own FAQ describes the model precisely: most wellness treatments can be prescribed through asynchronous review, a licensed medical provider reviews your intake forms and determines eligibility, and providers will consult with you directly if a synchronous visit is required. The lab workflow is stated plainly — Kingdom orders the labs, you get a lab order by email and schedule a draw at a local LabCorp, and the cost is "paid to Kingdom as part of your care", which means billed to you rather than covered by the plan. Naming a chief medical officer and individual nurse practitioners is real disclosure. What is missing is everything downstream: the compounding pharmacy is described only as an FDA-registered US pharmacy and never named, no state availability list is published, and the empty Peptides category means the navigation itself overstates what is on sale.

Every price on the platform is attached to a plan length, and no product offers a month-to-month option. Testosterone cypionate is $99 a month on a 2.5-month plan, $89 on six months and $79 on twelve. NAD⁺ is $79 a month on a 2.5-month plan. Sermorelin is $233 a month on a three-month plan. On top of that sits a recurring lab fee the site states as $149 every six months, with more frequent testing possible at provider discretion. So the honest first-year figure for testosterone is the plan cost plus two lab fees, not the sticker. So there is no true monthly price here: a per-month number that only exists inside a minimum commitment, with a separate recurring charge outside it, is a plan rate. The site's "no hidden fees" framing is accurate in the narrow sense that the lab fee is disclosed — but it is disclosed inside an FAQ answer, not next to the price. Ask what your total first-year outlay is, including labs, before committing to a twelve-month plan.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The site states its compounded GLP-1 and GLP-1/GIP medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality, which is the correct disclosure, and it states that medications are prescribed by a licensed physician and dispensed from an FDA-registered US pharmacy — a facility it does not name. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the catalog spans the whole range. Testosterone replacement has a large randomized safety base and requires ongoing hematocrit, PSA and testosterone monitoring; the required lab work here supports that, though the schedule is provider-discretionary. Enclomiphene has real data on raising testosterone and thinner data on symptoms and long-term safety. Sermorelin acts on a real growth-hormone axis with thin long-term human outcome data. Injected NAD⁺ has no controlled human outcome trials; oral NR and NMN raise a biomarker. Glutathione has essentially no controlled human outcome data. PT-141 is an approved molecule for one narrow indication in premenopausal women, so most prescribing of it is off-label use. Individual results vary.